Masimo (MASI) announced the FDA 510(k) clearance of expanded indications for the delta hemoglobin parameters provided with O3 Regional Oximetry. The parameters display relative changes in hemoglobin that can help clinicians identify the underlying mechanisms responsible for changes in tissue oxygen saturation. With this latest clearance, this capability is now available for use in both cerebral and somatic applications as well as for all patient populations, including pediatric and neonatal patients.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MASI:
- Video: Why Masimo Is Sliding Today
- Buy Rating for Masimo Amid Legal Opportunities and Market Conditions
- BTIG sees buying opportunity in Masimo weakness after Apple Watch news
- Masimo Corp. Earnings Call Highlights Growth and Resilience
- Cautious Outlook on Masimo: Hold Rating Amid Mixed Financial Signals and Strategic Adjustments